Search Result

Results for "

ABCG2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (1) Autophagy (1) Bacterial (2) BCRP (16) Btk (1) c-Kit (2) EGFR (1) GLUT (1) Hedgehog (1) Isotope-Labeled Compounds (2) P-glycoprotein (1) Parasite (3) PDGFR (3) Phosphodiesterase (PDE) (1) Small Interfering RNA (siRNA) (3) Sodium Channel (1) URAT1 (2) VEGFR (2)
By Research Areas:	Cancer (19) Cardiovascular Disease (2) Infection (5) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS00077

ABCG2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABCG2 Human Pre-designed siRNA Set A contains three designed siRNAs for ABCG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABCG2 Human Pre-designed siRNA Set A ABCG2 Human Pre-designed siRNA Set A

HY-RS00078

Abcg2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abcg2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Abcg2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abcg2 Mouse Pre-designed siRNA Set A Abcg2 Mouse Pre-designed siRNA Set A

HY-RS00079

Abcg2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Abcg2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Abcg2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Abcg2 Rat Pre-designed siRNA Set A Abcg2 Rat Pre-designed siRNA Set A

HY-155652

ABCG2-IN-1	BCRP	Cancer
ABCG2-IN-1 (compound K2), a Ko143 analog, is an orally active *ABCG2* inhibitor with an IC₅₀ of 0.13 μM. ABCG2-IN-1 has favorable oral pharmacokinetic profiles in mice .

HY-155653

ABCG2-IN-2	BCRP	Cancer
ABCG2-IN-2 is a potent *ABCG2* inhibitor with favorable oral pharmacokinetic profiles in mice. ABCG2-IN-2 can be used for the research of tumor multidrug resistance (MDR) and erythropoietic protoporphyria (EPP) .

HY-N2651

5,7,3'-Trihydroxy-4'-Methoxy-8-prenylflavanone	BCRP	Cancer
5,7,3'-Trihydroxy-4'-Methoxy-8-prenylflavanone (compound 1), a flavonoid, is a potent *ABCG2* inhibitor with an IC₅₀ of 6.6 μM .

HY-146676

UR-MB108

BCRP Cancer

UR-MB108 (Compound 57) is a potent, selective ABCG2 (BCRP) inhibitor with an IC₅₀ of 79 nM. UR-MB108 is stable in blood plasma .
HY-N2143

Fumitremorgin C

3 Publications Verification

12α-Fumitremorgin C
BCRP Bacterial Antibiotic Infection Cancer

Fumitremorgin C is a potent and selective ABCG2/BRCP inhibitor.

UR-MB108	BCRP	Cancer
UR-MB108 (Compound 57) is a potent, selective ABCG2 (BCRP) inhibitor with an IC₅₀ of 79 nM. UR-MB108 is stable in blood plasma .

Fumitremorgin C 3 Publications Verification 12α-Fumitremorgin C	BCRP Bacterial Antibiotic	Infection Cancer
Fumitremorgin C is a potent and selective *ABCG2/BRCP* inhibitor.

HY-149469

3,7,2',4'-Tetramethoxy-5-hydroxyflavone	BCRP	Cancer
BCRP/ABCG2-IN-1 is the inhibitor of breast cancer resistance protein (BCRP/ABCG2), with IC₅₀ of 5.98 μM, that can be used in multidrug resistance of breast cancer .

HY-111678

ML230 CID44640177; SID 88095709	BCRP	Cancer
ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC₅₀s values of 0.13 μM and 4.65 μM, respectively .

HY-B1153A

Glafenine hydrochloride Glafenin hydrochloride	Others	Inflammation/Immunology
Glafenine hydrochloride is a non-narcotic analgesic and non-steroidal anti-inflammatory drug. It is an *ABCG2* inhibitor with an IC₅₀ of 3.2 μM.

HY-136450

Triclabendazole sulfoxide TCBZ-SO	Parasite BCRP	Infection
Triclabendazole sulfoxide (TCBZ-SO) is the main plasma metabolite of Triclabendazole, and exhibits anti-parasite effects. Triclabendazole sulfoxide can inhibit membrane transporter *ABCG2/BCRP* ^[2].

HY-18010

PCI 29732 3 Publications Verification	Btk BCRP	Inflammation/Immunology
PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i ^app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of *ABCG2* by competitively binding to the ATP-binding site of ABCG2 ^[2].

HY-122416

6,8-Diprenylnaringenin Lonchocarpol A; Senegalensin	BCRP	Metabolic Disease Cancer
6,8-Diprenylnaringenin (Lonchocarpol A; Senegalensin), a hop prenylflavonoid, is a inhibitor of breast cancer resistance protein (BCRP/ABCG2). 6,8-Diprenylnaringenin inhibits ABCG2-mediated efflux of Mitoxantrone, and ³H-Methotrexate transport (IC₅₀=0.41 μM) in HEK293 cells. 6,8-Diprenylnaringenin exhibits some estrogenicity, but its potency is less than 1% of that of 8-Prenylnaringenin ^[2].

HY-10010

Ko 143 Maximum Cited Publications 32 Publications Verification	BCRP	Cancer
Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters ^[2].

HY-129301

CCTA-1523

BCRP Cancer

CCTA-1523 is a potent, selective, reversible and orally active ABCG2 inhibitor. CCTA-1523 shows cytotoxicity. CCTA-1523 shows anticancer activity .

CCTA-1523	BCRP	Cancer
CCTA-1523 is a potent, selective, reversible and orally active *ABCG2* inhibitor. CCTA-1523 shows cytotoxicity. CCTA-1523 shows anticancer activity .

HY-136450S

Triclabendazole sulfoxide-d3 TCBZ-SO-d₃	Isotope-Labeled Compounds Parasite BCRP	Infection
Triclabendazole sulfoxide-d₃ is the deuterium labeled Triclabendazole sulfoxide. Triclabendazole sulfoxide (TCBZ-SO) is the main plasma metabolite of Triclabendazole, and exhibits anti-parasite effects. Triclabendazole sulfoxide can inhibit membrane transporter ABCG2/BCRP[1][2].

HY-156092

Antitumor photosensitizer-4	BCRP Apoptosis	Cancer
Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .

HY-136450S1

Triclabendazole sulfoxide-13C,d3 TCBZ-SO-¹³C,d₃	Isotope-Labeled Compounds Parasite BCRP	Infection
Triclabendazole sulfoxide- ¹³C,d₃ is the ¹³C- and deuterium labeled Triclabendazole sulfoxide. Triclabendazole sulfoxide (TCBZ-SO) is the main plasma metabolite of Triclabendazole, and exhibits anti-parasite effects. Triclabendazole sulfoxide can inhibit membrane transporter ABCG2/BCRP[1][2].

HY-112505

Efflux inhibitor-1	BCRP	Cancer
Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward *ABCG2/BCRP* over ABCB1 with IC₅₀s of 0.45 μM and 2.17 μM, respectively .

HY-10440

Vismodegib 30+ Cited Publications GDC-0449	Hedgehog Autophagy	Cancer
Vismodegib (GDC-0449) is an orally active hedgehog pathway inhibitor with an IC₅₀ of 3 nM. Vismodegib also inhibits P-gp, *ABCG2* with IC₅₀ values of 3.0 μM and 1.4 μM, respectively ^[2].

HY-P5391

LL-37(17-32)	Bacterial	Others
LL-37(17-32) is a biological active peptide. (This peptide is an active segment of LL-37, a peptide derived from the C-terminal domain of human cathelicidin antimicrobial peptide. It has been reported that the LL17-32 peptide exhibits reversal effect on ABCG2-mediated multidrug resistance in cancer cell lines.)

HY-113805

MC70	P-glycoprotein	Cancer
MC70 is a potent and non-selective P-glycoprotein (P-gp) inhibitor with an EC₅₀ of 0.69 µM. MC70 is an ABC transporters inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1 ^[2].

HY-103439

GW583340 dihydrochloride	EGFR	Cancer
GW 583340 dihydrochloride is a potent dual *EGFR/ErbB2* tyrosine kinase inhibitor (IC₅₀: 0.01 and 0.014 μM respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity ^[2] .

HY-100933

MY-5445	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology Cancer
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter *ABCG2*, with anti-proliferative effect ^[2].

HY-144305

KPH2f	URAT1 GLUT	Infection
KPH2f is a safe, orally active, and effective dual URAT1/GLUT9 inhibitor with IC₅₀s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC₅₀=32.14 and 26.74 μM) .

HY-11079

A-803467 1 Publications Verification	Sodium Channel	Neurological Disease Inflammation/Immunology
A-803467 is a potent and selective tetrodotoxin-resistant Na_v1.8 sodium channel blocker (IC₅₀=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter ^[2].

HY-101561

Avapritinib 5 Publications Verification BLU-285	c-Kit PDGFR	Cancer
Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC₅₀s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 ^[2].

HY-10527C

Telatinib mesylate 1 Publications Verification Bay 57-9352 mesylate	VEGFR PDGFR c-Kit	Cancer
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active *VEGFR2, VEGFR3, PDGFα, and c-Kit* inhibitor with IC₅₀s of 6 nM, 4 nM, 15 nM and 1 nM, respectively .

HY-151432

URAT1 inhibitor 3	URAT1	Inflammation/Immunology
URAT1 inhibitor 3 is a potent, orally active, selective URAT1 inhibitor with an IC₅₀ value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi .

HY-109019

Vorolanib CM082; X-82	VEGFR PDGFR	Cardiovascular Disease Cancer
Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895) ^[2].

LL-37(17-32)	Bacterial	Others
LL-37(17-32) is a biological active peptide. (This peptide is an active segment of LL-37, a peptide derived from the C-terminal domain of human cathelicidin antimicrobial peptide. It has been reported that the LL17-32 peptide exhibits reversal effect on ABCG2-mediated multidrug resistance in cancer cell lines.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2143

Fumitremorgin C 3 Publications Verification 12α-Fumitremorgin C	Infection Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	BCRP Bacterial Antibiotic
Fumitremorgin C is a potent and selective *ABCG2/BRCP* inhibitor.